 | |
| Clinical data | |
|---|---|
| Other names | Edogesterone; PH-218; 17α-Acetoxy-3,3-ethylenedioxy-6-methylpregn-5-en-20-one |
| Drug class | Progestogen;Progestogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C26H38O5 |
| Molar mass | 430.585 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Edogestrone (INNTooltip International Nonproprietary Name,BANTooltip British Approved Name) (developmental code namePH-218), oredogesterone, also known as17α-acetoxy-3,3-ethylenedioxy-6-methylpregn-5-en-20-one, is asteroidalprogestin andantiandrogen of the17α-hydroxyprogesterone group which wassynthesized in 1964 but was never marketed.[1][2] Similarly to the structurally related steroidcyproterone acetate, edogestrone binds directly to theandrogen receptor andantagonizes it, displacingandrogens liketestosterone from the receptor, though not as potently as cyproterone acetate.[3] The drug has also been found to suppressandrogen production, likely viaprogesterone receptor activation-mediatedantigonadotropic activity.[4]
Geller has also demonstrated significant decreases in plasma or urine testosterone glucuronide levels following the administration of three other anti-androgens. These include Delalutin, Chlormadinone acetate, and PH-218. It would appear that decreased androgen production is a property shared by all anti-androgens to date.
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
